Reaction
Pouchitis reporting signals
As of the last recalculation, Pouchitis appears in 851 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is VEDOLIZUMAB (PRR 54.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Vedolizumab | 157 | 54.4 | 54.5 |
| Isotretinoin | 82 | 44.8 | 44.8 |
| Diphenoxylate Hydrochloride And Atropine Sulfate | 21 | 38.4 | 38.5 |
| Metronidazole | 88 | 37.5 | 37.5 |
| Ciprofloxacin Hydrochloride And Hydrocortisone | 30 | 36.5 | 36.6 |
| Metronidazole Topical | 53 | 28.9 | 29.0 |
| Adalimumab-Fkjp | 49 | 27.4 | 27.4 |
| Ciprofloxacin | 89 | 26.4 | 26.4 |
| Adalimumab-Aaty | 48 | 26.2 | 26.3 |
| Adalimumab-Adaz | 52 | 25.6 | 25.6 |
| Ciprofloxacin Hydrochloride | 91 | 25.5 | 25.5 |
| Loperamide Hydrochloride And Dimethicone | 32 | 25.3 | 25.4 |
| Mesalamine | 53 | 24.5 | 24.6 |
| Ciprofolxacin | 59 | 21.6 | 21.6 |
| Ciprofloxacin Tablets | 59 | 21.6 | 21.6 |
| Voriconazole Injection | 18 | 20.7 | 20.7 |
| Mercaptopurine | 14 | 20.1 | 20.1 |
| Ursosiol | 15 | 19.2 | 19.2 |
| Infliximab | 142 | 18.9 | 18.9 |
| Loperamide Hydrochloride | 32 | 18.1 | 18.2 |
| Ursodiol | 15 | 17.1 | 17.1 |
| Minocycline | 8 | 16.9 | 16.9 |
| Terbinafine Hydrochloride | 6 | 16.6 | 16.6 |
| Rifaximin | 13 | 15.4 | 15.4 |
| Tofacitinib Citrate | 8 | 15.1 | 15.1 |
| Voriconazole | 18 | 14.8 | 14.8 |
| Risankizumab-Rzaa | 44 | 13.8 | 13.8 |
| Ustekinumab | 33 | 8.2 | 8.2 |